Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409419 · ClinicalTrials.gov registry record
PET Imaging of the Immune System Using Analog Probes
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- 4
- Enrollment target
NCT03409419 is a clinical trial that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT03409419 has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The goal of this proposal is to assess the biodistribution of 18F-Clofarabine, a new tracer developed for use in PET/CT scans. The investigator's hypothesis is this tracer will allow for imaging immune activation in patients with melanoma before and after treatment with immunotherapy. A maximum of 10 subjects are intended to be included in this study. Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans, with each visit taking up to 4 hours. The first visit will be prior to the first cycle of immunotherapy treatment, and the second scan will take place 2-4 weeks after the immunotherapy treatment has started. Prior to the PET scan an IV line will be placed. Blood pressure, heart rate, blood oxygen and ECG will be obtained. Then the 18F-Clofarabine will be injected and the PET/CT scan acquisition started. After a maximum of 120 min of scanning, subjects will undergo again blood pressure, heart rate, blood oxygen and ECG.
Interventions
- DRUG [18F] CFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2020-11-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409419
The ClinicalTrials.gov registry entry for NCT03409419 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] CFA is the first listed.
NCT03409419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03409419 about?
NCT03409419 is a clinical study titled "PET Imaging of the Immune System Using Analog Probes". The goal of this proposal is to assess the biodistribution of 18F-Clofarabine, a new tracer developed for use in PET/CT scans. The investigator's hypothesis is this tracer will allow for imaging immune activation in patients with melanoma before and after treatment with immunotherapy. A maximum of ...
What is the current status of trial NCT03409419?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2018-04-10. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT03409419?
The interventions under investigation include: [18F] CFA (DRUG).
Who is sponsoring clinical trial NCT03409419?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.